To observe the effect of treatment of allergic rhinitis(AR) on the control of bronchial asthma(BA).

From January 2009 to May 2010, 65 infantile bronchial asthma and allergic rhinitis were randomly divided into observation group (n=35) and control group(n=30). There had no significant difference of age, gender, degree of bronchial asthma severity before treatment, lung function [peak expiratory flow (PEF)] between two groups (P>0.05). The study protocol was approved by the Ethical Review Board of Investigation in Human Being of Centre for Ya'an People's Hospital of Sichuan Province. Informed consent was obtained from all participants. Both groups received regular use of inhaled with fluticasone propionate aerosol (100-500) μg/d according to degrees of bronchial asthma severity. Observation group simultaneously with budesonide nasal spray on both sides of the nose, each one gush (64 μg/spray) for the first month, twice a day. In the second month, both sides of the nose, a spray once a day, and in the third month every other day on both sides of the nose. The treatment lasted for 3 months. After treatment for 6 months, clinical curative effects and pulmonary function changing of two groups were observed.

Total effectiveness was 94.2% (33/35) for observation group and 73.3% (22/30) for control group with a significant difference (P<0.05). Lung function improvement (peak expiratory flow) after the treatment between observation group [(85.73±5.42)%] and control group [(81.95±4.31)%] had a statistically significant difference (P<0.05).

Children with bronchial asthma and allergic rhinitis should receive active treatment to control bronchial asthma.